April 28, 2023

8:30-9:00 – Plenary lecture

Jürgen Götz (Australia)Tau biology, tau vaccines and therapeutic ultrasound

9:00-11:00 – Session 4 – Tau aggregation (L Serpell & Y Fichou)

  • 9:00 – Eckhard Mandelkow (G) Recent insights into Tau seeding and phosphorylation
  • 9:15 – Louise Serpell (UK) Phase separation of a paired-helical filament forming region of tau
  • 9:25 – Yann Fichou (F) Mutations in tau protein influence aggregation propensity through conformation modulation
  • 9:35 – Claudio Gomes (P) Chaperone modulation of tau aggregation and condensation
  • 9:45 – Maria Cacho Barraza (UK) Hydromethylthionine first, rivastigmine second: cognitive effects of single versus combination therapies in tau transgenic mice
  • 9:55 – Richard McKenney (USA) Oligomerization of Tau on Microtubules
  • 10:05 – Alessia Santambrogio (UK) A brain-seeded fibril amplification models the aggregation process of tau in Alzheimer’s disease for drug discovery
  • 10:15 – Nicolò Bisi (F) Methods to assess the activity of drug candidates on tau aggregation and tau microtubule dynamics
  • 10:25 – Kapil V. Ramachandran (USA) A new mechanism of endogenous Tau aggregation through ApoE / neuro-proteasome complexes
  • 10:35 – Questions

10:50-11:20 Coffee break

11:20-13:00 Session 5Tau toxicity (M Gratuze & P Dourlen)

  • 11:20 – Maria Elena Avale (Arg) Local tau reduction rescues pathological phenotypes in a preclinical model of tauopathy
  • 11:30 – Maud Gratuze (F) TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4
  • 11:45 – Stephanie Fowler (UK) Short tau filaments are packaged into extracellular vesicles in AD brain
  • 11:55 – Pierre Dourlen (F) Presynaptic toxicity of the AD risk gene Bin1
  • 12:05 – Lovesha Sivanantharajah (UK) Neuronal vulnerability to tau-mediated toxicity is characterized by a broad spectrum of varying responses
  • 12:15 – Katerina Papanikolopoulou (Gr) Mical modulates Tau toxicity via cysteine oxidation in vivo
  • 12:25 – Patrik Verstreken (B) Tau toxicity at the synapse
  • 12:40 – Questions

12:55-14:15 Lunch & Poster exhibition

14:15-15:40 Session 6 (Chairs: C. Panzi & I. Sotiropoulos)

  • 14:15 – Illana Gozes (Israel) Protection against tauopathy is influenced by sex
  • 14:25 – Ioannis Sotiropoulos (Gr/P) Persistent pain causes Tau-mediated hippocampal malfunction and memory deficits
  • 14:35 – Geoffrey Canet (Ca) Tau secretion is driven by circadian variations of body temperature during the sleep/wake cycle: implications for tau spreading in Alzheimer’s disease
  • 14:45 – Chiara Panzi (UK) Investigating the synaptic mechanisms of the spread of wild type and P301S 1N4R human tau in in vitro and in vivo models
  • 14:55 – Florent Sauvé (F) A direct CSF-to-blood Tau transport: the tanycytic clearance.
  • 15:05 – Daniel Chain (USA) High amount and fast production of tauC3 in PS19 mice
  • 15:15 – Rayane Hedna (F) New Thiazole-Flavone Hybrid Compounds Binding to Tau Protein and With Antitumor Activity Against Glioblastoma
  • 15:25 -Questions

15:40-16:15 Coffee break

16:15-17:30 Session 7Tau therapy (I Dewachter & JP Brion)

  • 16:15 – Ilse Dewachter (Belgium) ApoE, inflammation and tau in AD: a road towards multi-targeted therapies
  • 16:30 – Claude Wischik (UK) Phase 3 outcomes for tau aggregation inhibitor in Alzheimer’s
  • 16:45 – Isabel Lastres Becker (Sp) Neuroprotective effects of CB2 cannabinoid receptor antagonists’ treatment in TAU-dependent Frontotemporal Dementia
  • 16:55 – Dina Rodrigues Martins (B) Targeting intracellular tau with intrabodies
  • 17:05 – Philippe Verwaerde (France) AZP2006 Phase2a in Progressive Supranuclear Palsy patients
  • 17:15 – Questions

17:30 Poster prize and farewell